



25
years growth, connection, inspiration

Solving Diabetes Mysteries:
A Case-by-Case Approach and
Standards of Care Update 2026



Scan to visit
<https://diabetesed.net/hawaii-2026/>
Handouts and
Resources Here
Scan to View

EDUCATION FOR HEALTHCARE PROFESSIONALS

Beverly Thomassian, RN, MPH, BC-ADM, CDCES
Pronouns: She, her and hers
Founder - www.DiabetesEd.net

1

Hawaii ADCES Coordinating Body



Hawaii Chapter President Naomi Fukuda, APRN, BC-ADM, CDCES
Camlyn Masuda, PharmD, CDCES, BCACP & Kourtney Inoue

2



25
years growth, connection, inspiration

Thinking about taking the CDCES Exam?

CDCES Deluxe Prep Bundle on DiabetesEd
Online University only \$299
(usually \$499).

Use coupon code Aloha26.
Will be active for 1 year. Expires on Sept 25 , 2027.

www.DiabetesEd.net (search Hawaii)

3

Speakers & Agenda

08:00 am – 09:40 am | Updates to the ADA Standards of Care
Presenter: Beverly Thomassian

09:40 am – 10:10 am | Break and visit exhibitors

10:10 am – 11:50 am | Identify the key elements of the standards that improve clinical care for people with diabetes

11:50 am – 1:00 pm | Lunch and visit exhibitors

1:00 pm – 2:05 pm | Diabetes Mysteries Case Studies

2:05 pm – 2:25 pm | Break and visit exhibitors

2:25 pm – 3:30 pm | Exploring Lesser-Known Diabetes Complications


3:30 pm – 4:30 pm | Complex diabetes presentations in clinical care

• *Presenter: Dr. Alan Parsa*

4

Coach Bev has no Conflict of Interest

- ▶ She's not on any speaker's bureau.
- ▶ Does not invest or have any financial relationships with diabetes related companies.
- ▶ Gathers information from reading package inserts, research and articles.
- ▶ The ADA Standards of Medical Care is main resource for course content.



5

Standards of Care Update & Solving Diabetes Mysteries

Objectives:

1. State 3 changes and updates to the annual ADA Standards of Medical Care in Diabetes.
2. List at least one key element of the discussed standards that improve clinical care for people with diabetes.
3. Describe strategies to use the ADA hyperglycemia algorithm to determine appropriate use of the latest medications that address hyperglycemia and cardiorenal health.
4. Explore case studies that delve into unusual presentations of diabetes and co-conditions.
5. Describe identification of lesser-known complications of diabetes such as cancer, PMOS, obstructive sleep apnea, sexual dysfunction, eye and dental issues.
6. Share practical approaches to treat a variety of diabetes presentations in clinical care.



6

17. Diabetes Advocacy

- ▶ People living with diabetes deserve to be free from the burden of discrimination.
- ▶ We need to all be a part of advocating to ensure a healthy and productive life for people living with diabetes.
- ▶ Make sure cost is not a barrier to diabetes self-management.



Diabetes Care needs to meet outlined standards in all settings.

- In school setting
- Young children in childcare
- For Drivers
- In work settings
- In Detention Facilities
- Insulin Access & Affordability

17. Diabetes Advocacy: Standards of Care in Diabetes—2026

American Diabetes Association Professional Practice Committee for Diabetes

7

CDC Announces




35% of
Americans will
have Diabetes
by 2050

Boyle, Thompson, Barker, Williamson
2010, Oct 22:8(1)29
www.pophealthmetrics.com

8

Poll Question 1

- ▶ What percent of adults in the U.S. are living with undiagnosed and diagnosed type 2 diabetes?
- ▶ A. About 30%
- ▶ B. 11.3%
- ▶ C. 14.7%
- ▶ D. 25.6%



9

Type 2 Diabetes in America 2026

- ▶ 14.7% with Diabetes - 38 million adults
- ▶ 25% don't know they have it
- ▶ 44% with Prediabetes – 115+ million adults

Figure 3. Age-adjusted, county-level prevalence of diagnosed diabetes among adults aged 20 years or older, United States, 2004, 2012, and 2019



Data sources: US Diabetes Surveillance System; Behavioral Risk Factor Surveillance System.

<https://gis.cdc.gov/grasp/diabetes/diabetesatlas-statsreport.html>

10

Diabetes in Hawaii



The Burden of Diabetes in Hawaii

Diabetes is an epidemic in the United States. According to the Centers for Disease Control and Prevention (CDC), over 38 million Americans have diabetes and face its devastating consequences. What's true nationwide is also true in Hawaii.

Hawaii's diabetes epidemic:

- Approximately 130,200 adults in Hawaii, or 9.5% of the adult population, have diagnosed diabetes.
- Every year, an estimated 10,000 adults in Hawaii are diagnosed with diabetes.

The serious complications of diabetes include heart disease, stroke, amputation, end-stage kidney disease, blindness—and death.

Diabetes Is Expensive

- 136 million Americans have diabetes or prediabetes
- 1.2 million Americans are diagnosed with diabetes every year
- About 1 in 3 seniors in the United States has diabetes
- Diabetes contributes to the death of nearly 400,000 Americans annually

ADA
Diabetes.org
2024

11

Asian Americans, Native Hawaiians and Pacific Islanders are at greater risk for type 2 diabetes at any weight.

YOU COULD BE AT RISK TOO:
If you can check one of these boxes, you are at risk for type 2 diabetes:

- I am of Asian descent
- I am of Hawaiian descent
- I am of Pacific Islander descent
- I am overweight/obese
- I do not exercise regularly
- I am over 45 years old
- I have family members with diabetes

WHAT IS DIABETES?
Diabetes is a disease that affects every part of your body. If untreated, diabetes can lead to heart attack, stroke, kidney disease, blindness, amputations and death.

The good news is you can prevent or delay getting type 2 diabetes by eating healthy and getting regular exercise activity.

Ask your doctor if you should be screened for type 2 diabetes.

STOP DIABETES
The American Diabetes Association is committed to supporting those at risk. Asian Americans and Native Hawaiians are among the most at risk. For more information about diabetes and to get involved, call 1-800-DIABETES (1-800-342-2383) or visit diabetes.org.

Disparities in Diabetes Prevalence Among Native Hawaiians/Other Pacific Islanders and Asians in Hawai'i

Diabetes is most prevalent among the following populations in Hawai'i:

According to data tracked by [America's Health Rankings](https://drc.jabsom.hawaii.edu/diabetes-in-hawaii/index.html) and researchers at the [John A. Burns School of Medicine](https://drc.jabsom.hawaii.edu/diabetes-in-hawaii/index.html), Native Hawaiians, Pacific Islanders, and Filipino residents have disproportionately high rates, with **22.4% of Native Hawaiians** being diagnosed with diabetes.

compared with 5 - 7% of white residents of the state.

<https://drc.jabsom.hawaii.edu/diabetes-in-hawaii/index.html>

ORIGINAL RESEARCH • Volume 18 • February 23, 2018

12

Diabetes Prevalence Stats

For adults in U.S., diabetes prevalence:

- American Indians and Alaska Natives – highest rates
- Non-Hispanic Blacks (17.4%),
- People of Hispanic origin (15.5%),
- Non-Hispanic Asians (16.7%)
- White Individuals (13.6%)

Education and SES and Location

- ▶ Less than high school ed (13.1%)
- ▶ More than high school (6.9%)
- ▶ Living below federal poverty (13.1%)
- ▶ Living at 500% of federal poverty (5.1%)
- ▶ Rural living (9.5%)
- ▶ Metropolitan (8.1%)

1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes—2025
Copyright 2025 American Diabetes Association. All rights reserved.

13


Income Disparity

MEDIAN HOUSEHOLD INCOME




Median annual income is significantly lower for NH/PI households compared to White households.

FAMILY INCOME



Families with Native Hawaiian ancestry report lower median incomes than the state overall.

HOURLY WAGES



NH/PI workers consistently earn lower median hourly wages than their White counterparts.

Data Sources: National Equity Atlas via Hawaii Applied

***A complex issue impacting well-being and opportunity.**

14

THE INTERSECTION OF POVERTY AND HEALTH EQUITY

JOHN HOPKINS MEDICINE FRAMEWORK: HEALTH EQUITY WORK

Expert **Dr. Sherita Golden** emphasizes addressing underlying social and economic determinants rather than focusing on race alone.



Dr. Sherita Golden,
Johns Hopkins
Medicine Expert

Shared Across

Demographics: While diabetes burdens specific racial groups differently, poverty creates a common thread of structural and environmental hardship across diverse regions like Appalachia, Mississippi, and New Mexico.

Broadening the Lens:

Health equity work requires addressing underlying social and economic determinants rather than focusing on race alone.

15

Social Determinants (Drivers) of Health

WHAT ARE SOCIAL DETERMINANTS OF HEALTH (SDOH)?

NON-MEDICAL FACTORS:
The conditions in the environments where people are born, live, learn, work, play, worship, and age that affect a wide range of health, functioning, and quality-of-life outcomes.

THE SPECTRUM OF SDOH

OVERALL WELL-BEING

GREATER IMPACT:
Research suggests SDOH may have a greater impact on health than clinical care alone.

ECONOMIC STABILITY
[Income]
[Employment]
[Medication Affordability]

EDUCATION
[Health Literacy]
[Language Barriers]
[Access to Information]

HEALTHCARE ACCESS
[Insurance Coverage]
[Transportation]
[Specialist Availability]

NEIGHBORHOOD & ENVIRONMENT
[Safe Places to Exercise]
[Access to Healthy Foods]
[Housing Stability]

SOCIAL & COMMUNITY CONTEXT
[Family Support]
[Social Isolation]
[Discrimination]
[Community Resources]

DIABETES-SPECIFIC SDOH EXAMPLES

- [A person can't exercise outside for safety reasons]
- [They live in a food desert]
- [Lack of **affordable medication** prevents proper management]

[Data Sources & Impact Metrics: Life Expectancy, Disease Incidence, Cost]

Graphic generated with <https://chat.openai.com/chat>

16

Status of Diabetes Care

- ▶ In 2015–2018, U.S. community-dwelling adults with diabetes achieved:
 - ▶ A1C <7% by 50.5%
 - ▶ 75.4% achieved A1C <8%.
 - ▶ BP target of <130/80 achieved by 47.7%
 - ▶ 70.4% achieved blood pressure <140/90 mmHg.
 - ▶ Lipid control (non-HDL cholesterol) <130 mg/dL, achieved by 55.7%
- ▶ **22.2% met targets for all three risk factors**
- ▶ **Many not receiving adequate lifestyle or pharmacotherapy.**



1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes—2023

17

Rising Complication Rates


- ▶ Since 2010, adults with diabetes across the U.S. complication rates are increasing for:
 - ▶ kidney failure,
 - ▶ nontraumatic lower-extremity amputations,
 - ▶ stroke,
 - ▶ heart failure, and
 - ▶ hyperglycemic crises
- Rates of myocardial infarction have plateaued, reversing decades of earlier improvements




1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes—2023

18

Let's meet people where they are at.



19



20

HORMONAL REGULATION OF BLOOD GLUCOSE			
HORMONE & ORIGIN		EFFECT ON BLOOD GLUCOSE	
	Glucagon (pancreas)		INCREASES Glycogen → Glucose Glycogenolysis in Liver
	Stress hormones (kidney)		INCREASES Promotes Gluconeogenesis & Insulin Resistance
	Epinephrine (kidney)		INCREASES Rapid Liver and Muscle Glycogenolysis
	Insulin (pancreas)		DECREASES Glucose → Fat Glucose Uptake (Muscle/Fat)
	Amylin (pancreas)		DECREASES Suppresses Post-meal Glucagon
	Gut hormones		
a.	Incretins (GLP-1) released by L cells of small intestine and colon		DECREASES Enhances Insulin, Slows Gastric Emptying
b.	GIP found in K cells in duodenum and some in small intestine		DECREASES Enhances Insulin Response

21


Poll Question 2

- Which of the following level is considered diabetes range?
- Random BG of 211
 - A1c of 5.9 %
 - After meal BG of 197
 - Fasting BG 119



22

2. Diagnosis and Classification of Diabetes | Natural History of Diabetes



23

Pre Diabetes & Type 2- Screening Guidelines (ADA 2026 Clinical Practice Guidelines)

- Start screening all people at age 35.
- Screen at any age if BMI ≥ 25 (Asians BMI ≥ 23) plus one or > additional **risk factor**:
 - First-degree relative w/ diabetes
 - Member of a high-risk ethnic population
 - Habitual physical inactivity
 - History of heart disease
 - Check more frequently if taking high risk meds; antiretrovirals, 2nd generation antipsychotics or steroids
 - History of pancreatitis, prediabetes, GDM, periodontal disease



24

Diabetes 2 - Who is at Risk?

(ADA 2024 Clinical Practice Guidelines)



Screen using A1C, Fasting Blood Glucose or OGTT.

Repeat screening at least every 3 years if negative.

*If prediabetes or on high risk meds, recheck yearly

3. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024

Risk factors cont'd

- ▶ HTN - BP > 130/80
- ▶ HDL < 35 or triglycerides > 250
- ▶ History of Gestational Diabetes Mellitus
- ▶ Polycystic ovary syndrome (PCOS)
- ▶ Other conditions associated w/ insulin resistance:
 - ▶ Elevated BMI, acanthosis nigricans (AN)


25

Diabetes Screening Guidelines

(ADA 2026 Clinical Practice Guidelines – Cheat Sheet)

RECOMMENDATIONS FOR DIAGNOSIS AND CLASSIFICATION OF DIABETES — 2026

CRITERIA FOR SCREENING FOR DIABETES AND PREDIABETES IN ASYMPTOMATIC ADULTS (BASED ON TABLE 1)



26

Poll Question 3

- ▶ What best describes prediabetes in the U.S.?
- a. Prediabetes affects 18-20% of people above the age of 20.
- b. Prediabetes is associated with increased risk of CV disease
- c. The prevalence of prediabetes and diabetes are almost equal.
- d. Most people with BMI of 30 or greater have prediabetes.



27

PREDIABETES is FREAKING ME OUT

 **115.2 million** people in US have prediabetes

 More than **44%** of adults (Over 2 in 5)

 **80%** don't know they have it

 In 3-5 years, **~30%** with prediabetes will develop diabetes

 Higher risk of **Heart Attack, Stroke, Neuropathy, Vessel Disease**



Do I look like I am freaking out?

Section 3: Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2026, American Diabetes Association

28

PreDiabetes in Youth at 30%



YOUNG PEOPLE AND PREDIABETES

1 IN 3 ADOLESCENTS BETWEEN 12-17 YEARS OLD HAVE PREDIABETES

INCREASES RISK OF TYPE 2 DIABETES, HEART DISEASE, STROKE

SOURCE: CDC


NEW CDC DATA ON TEENS & PREDIABETES



29

3. Prevent or Delay Diabetes for those with Prediabetes

- ▶ Prediabetes defined as:
 - ▶ A1c 5.7 – 6.4% or fasting BG 100 -125mg/dl
- ▶ Action:
 - ▶ Screen yearly for diabetes
 - ▶ For adults with BMI 23/25
 - ▶ Refer to DPP approved programs (can use certified tech assisted technologies.
 - ▶ Includes intensive behavioral lifestyle interventions with 3-7% wt reduction goal + 150 min exercise week
 - ▶ Provide in person or certified assisted programs



3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2026, ADA

30

DIABETES PREVENTION PROGRAM

FOLLOW A HEALTHY EATING PATTERN

EMPHASIZE WHOLE FOODS

Legumes Nuts Minimize refined & processed foods.

EVIDENCE-BASED EATING PATTERNS

- Mediterranean-style
- Low-carbohydrate
- Vegetarian or plant-based
- DASH (Dietary Approaches to Stop Hypertension)

GET REGULAR PHYSICAL ACTIVITY

GET ≥ 150 MINUTES/WEEK OF MODERATE-INTENSITY ACTIVITY
such as brisk walking.

INCLUDE RESISTANCE TRAINING
Include resistance training.

BREAK UP PROLONGED SEDENTARY TIME

Avoid excessive sitting. Take movement breaks.

ACHIEVING HEALTHY OUTCOMES

31

DPP Short Term & Long-Term Evidence

The U.S. DPP trial demonstrated intensive lifestyle intervention **Reduces risk of incident type 2 diabetes by 58% over 3 years.**

- ▶ In the U.S. Diabetes Prevention Program Outcomes Study (DPPOS) benefits continued:
 - ▶ 34% reduction at 10 years
 - ▶ 27% reduction at 15 years
 - ▶ 24% reduction at 21 years*

*major cardiovascular events were not significantly different from comp group 21 years after the DPP concluded.

1. Prevention or Delay of Diabetes and Associated Complications: Standards of Care in Diabetes—2026

32

Sleep quality and Diabetes Risk

- ▶ **Night owls have 2.5 higher odds for type 2 than early birds (chronotype)**
- ▶ Poor sleep quality associated with 40% increased risk of developing type 2 diabetes
- ▶ Sleep modulates important metabolic, endocrine, cardiovascular processes.
- ▶ Sleep quality “an individual’s self-satisfaction with all aspects of sleep experience.”

1. Prevention or Delay of Diabetes and Associated Complications: Standards of Care in Diabetes—2026

33

3. Metformin & Prediabetes

- ▶ Use metformin for prevention of type 2 for those at high risk:
 - ▶ 25–59 yrs with BMI ≥ 35
 - ▶ A1C 6.0% or more
 - ▶ History of GDM
- ▶ Consider Metformin to prevent hyperglycemia in high-risk individuals:
- ▶ Periodic assess of B12, esp if have anemia, peripheral neuropathy.



1. Prevention or Delay of Diabetes and Associated Complications
Standards of Care in Diabetes—2018

34

Common Oral Diabetes Meds



Delivering Success!
Get Our Free CDCES Coach App

Class/Main Action	Name(s)	Daily Dose Range	Considerations
Biguanides • Decreases hepatic glucose output • First line med at diagnosis of type 2	metformin (Glucophage)	500 - 2550 mg (usually BID w/ meal)	Side effects: nausea, bloating, diarrhea, B12 deficiency. To minimize GI Side effects, use XR and take w/ meals. Obtain GFR before starting. • If GFR <30, do not use. • If GFR <45, don't start Metformin • If pt on Metformin and GFR falls to 30-45, eval risk vs. benefit; consider decreasing dose. For dye study, if GFR <60, liver disease, alcoholism or heart failure, restart metformin after 48 hours if renal function stable. Benefits: lowers cholesterol, no hypo or weight gain, cheap. Approved for pediatrics, 10 yrs + Lowers A1c 1.0%-2.0%.
	Riomet (liquid metformin)	500 - 2550 mg 500mg/5mL	
	Extended Release-XR (Glucophage XR) (Glumetza) (Fortamet)	(1x daily w/ dinner) 500 - 2000 mg 500 - 2000 mg 500 - 2500 mg	

Biguanide derived from:
Goat's Rue *Galega officinalis*,
French Lilac
Does NOT harm kidneys
\$10 for 3-month supply from
Walmart & other pharmacies



35

Poll Question 5


- ▶ A 36-year-old has an A1C of 6.2%, BMI of 36, hypertension, and a strong family history of type 2 diabetes. Despite sustained nutrition and physical activity interventions, they can't seem to lower their A1C. They ask whether medication could help reduce their risk of developing type 2 diabetes. Which approach is MOST consistent with American Association of Clinical Endocrinology (AACE) recommendations?
- ▶ A. Avoid pharmacologic treatment until the A1C or FPG reaches the diagnostic threshold for diabetes.
- ▶ B. Consider pharmacotherapy, including metformin or GLP-1-based therapy to reduce metabolic risk.
- ▶ C. Initiate a sulfonylurea to improve beta-cell function and prevent progression to type 2 diabetes.
- ▶ D. Initiate basal insulin to preserve pancreatic beta-cell function and lower A1C.



36


GLP-1 Therapy for Prediabetes?

- ▶ GLP-1's for weight management with BMI of 25+ is highly beneficial - should be considered.
- ▶ Every kilogram of weight loss confers a 16% reduction in risk of progression over 3.2 years




3. Prevention or Delay of Diabetes and Associated Comorbidities
Standards of Care in Diabetes—2026

37




38



39


Incretins: GLP & GIP Receptor Agonists



GLP-1: glucagon like peptide 1
GIP: glucose-dependent insulinotropic polypeptide

40

GLP-1 Effects in Humans Understanding the Natural Role of Incretins




41

Pocket Card: GLP-1 & GIP RA


GLP-1 & GIP for Diabetes & Weight Loss

Class/Action	Generic Name	Diabetes Version Dose & Indications	Wt loss Version Max Dose & Indications	Considerations
GLP-1 RA - Glucagon Like Peptide Receptor Agonist	exenatide	exenatide 5 and 10 mcg		Side effects: N/V, wt loss. Report signs of pancreatitis or ileus, stop med.
"Incretin Mimetic"	liraglutide	Victoza† 0.6, 1.2, 1.8mg	Saxenda†† - 3.0mg	Black box warning: Avoid if family history medullary thyroid tumor. FDA approved to reduce Major Adverse CV Events; MI, Stroke, Death (except exenatide, Saxenda). †Approved for peds 10-17 yrs ††Approved for peds 12-17 years Lowers A1C ~ 0.5 - 1.6% Wt loss: 4-9% (Diabetes versions)
	dulaglutide	Trulicity† 0.75, 1.5, 3.0, 4.5mg		
	semaglutide	Ozempic 0.25, 0.5, 1.0, 2.0mg Tx for CKD	Wegovy†† - 2.4mg High Dose - 7.2mg Tx for MASH	
	semaglutide	Oral Ozempic 1.5, 4, 9 mg Rybelsus 3, 7, 14 mg	Wegovy - 25mg Oral tablet	
	semaglutide	Daily Oral - fasting w/ H2O		
GLP-1 & GIP Receptor Agonist	tirzepatide	Mounjaro† 1x week injection. 2.5, 5.0, 7.5, 10, 12.5, 15 mg. Single dose prefilled pen or vial. Gradually adjust dose based on shared decision, individual goals.	Zepbound Max dose 15mg Tx for sleep apnea	Side effects: N/V, wt loss. Report pancreatitis or signs of ileus, stop med. Black box warning: Avoid if family hx of medullary thyroid tumor. †Approved for peds 10-17 yrs Lowers A1C ~ 1.8 - 2.4% Wt loss: 7-14% (Diabetes versions)


42



43



44



45

Counseling Points: GLP-1 RA & GLP-1/GIP

- ▶ Avoid if personal or family history of medullary thyroid cancer or personal history of Multiple Endocrine Neoplasia type 2 (MEN-2)
- ▶ Avoid in combo with DPP-4 inhibitors
- ▶ Watch for intestinal obstruction
- ▶ Increased risk of biliary disease
- ▶ Education: Eat smaller meals to reduce nausea and limit high fat meals
- ▶ Use of non-FDA *compounded* products not recommended



If on tirzepatide and oral contraceptives, use back up contraception for first 4 weeks

46

Stopping GLP-1s is Common

SEMAGLUTIDE DISCONTINUATION IN OBESITY CARE

Nationwide Danish cohort
157,822 first-time users



Cohort
157,822 first-time users

Higher discontinuation risk
Age 10-29 vs 45-59:
RR 1.49 (95% CI 1.47-1.52)
Men vs women:
RR 1.46 (95% CI 1.14-1.17)

1 in 4 discontinuers
restarted within 3 months

Association, not causation

Madsen AL et al. JAMA Network Open. 2020;3(10):e2019275. doi:10.1001/jamanetworkopen.2020.19275

Sudden discontinuation of semaglutide and tirzepatide results in regain of one-half to two-thirds of the weight loss within 1 year.

Consider trying lowest effective dose, using intermittent therapy, or stopping medication followed by close weight monitoring.

47

Pocket Card: GLP-1 & GIP RA

GLP-1 & GIP for Diabetes & Weight Loss

Class/Action	Generic Name	Diabetes Version Dose & Indications	Wt loss Version Max Dose & Indications	Considerations
GLP-1 RA - Glucagon Like Peptide Receptor Agonist "Incretin Mimetic" • Increases insulin release with food • Slows gastric emptying • Promotes satiety • Suppresses glucagon	exenatide 2x day injection	exenatide 5 and 10 mcg		Side effects: N/V, wt loss. Report signs of pancreatitis or ileus, stop med. Black box warning: Avoid if family history medullary thyroid tumor. FDA approved to reduce Major Adverse CV Events; MI, Stroke, Death (except exenatide, Saxenda). Approved for peds 10-17 yrs Approved for Peds 12-17 years Lowers A1C ~ 0.5 - 1.6% Wt loss: 4-9% (Diabetes versions)
	liraglutide 1x day injection	Victoza [®] 0.6, 1.2, 1.8mg	Saxenda [®] - 3.0mg	
	dulaglutide 1x week injection	Trulicity [®] 0.75, 1.5, 3.0, 4.5mg		
	semaglutide 1x week injection	Ozempic 0.25, 0.5, 1.0, 2.0mg Tx for CKD	Wegovy [®] - 2.4mg High Dose - 7.2mg Tx for MASIH	
	semaglutide Daily Oral - fasting w/ H2O	Oral Ozempic 1.5, 4, 9 mg Rybelsus 3, 7, 14 mg	Wegovy - 25mg Oral tablet	
GLP-1 & GIP Receptor Agonist Activates receptors for GLP-1 (see above) & Glucose-dependent Insulinotropic Polypeptide (GIP).	tirzepatide 1x week injection. Single dose prefilled pen or vial. Gradually adjust dose based on shared decision, individual goals.	Mounjaro [®] 2.5, 5.0, 7.5, 10, 12.5, 15 mg. Reduces Major Adverse CV Events; MI, Stroke, Death	Zepbound Max dose 15mg Tx for sleep apnea	Side effects: N/V, wt loss. Report pancreatitis or signs of ileus, stop med. Black box warning: Avoid if family hx of medullary thyroid tumor. Approved for peds 10-17 yrs Lowers A1C ~ 1.8 - 2.4% Wt loss: 7-14% (Diabetes versions)

48



49

GLP-1 /GIPs Approved for Weight Loss

- ▶ **Liraglutide (Daily)**
 - ▶ Victoza 1.8 mg (diabetes)
 - ▶ Saxenda 3 mg (wt loss)
 - ▶ 6% wt loss, \$1349 a mo
- ▶ **Semaglutide:**
 - ▶ Ozempic 2mg (diabetes)
 - ▶ Wegovy 2.4mg (wt loss)
 - ▶ Wegovy 7.2mg (high dose)
 - ▶ Oral Wegovy 25mg (oral)
 - ▶ 6% wt loss, \$1349 a mo
- ▶ **Tirzepatide**
 - ▶ Mounjaro 15mg (diabetes)
 - ▶ Zepbound 15mg(wt loss)
 - ▶ 13% wt loss - \$1056 a mo

All 3 Approved for use in adults with a:

- ▶ BMI of ≥ 30 or
- ▶ BMI of ≥ 27 or greater who have hypertension, type 2 diabetes, or dyslipidemia.

Foundayo (Orforglipron): small-molecule, oral GLP-1 receptor agonist - a once-daily pill with no water or food restrictions – up to 17.2 mg daily

50

Incretin Therapy: Nutrition Strategies

Adverse Effect	Nutrition Intervention
Prevent Malnutrition & Sarcopenia	Sufficient protein (min. 60 gm, up to 1.2-1.5 gm/kg), Nutrient-dense foods eating pattern to support needs
Nausea	Encourage resistance training Small frequent meals Limit high fat foods Stay hydrated, limit carbonation
Constipation	Fiber, Fluids & Movement Consider stool softener as needed.
Diarrhea	Fiber & Fluids Limit sugar alcohols, coffee, dairy, alcohol and carbonation

Incretin-Based Therapies and Lifestyle Interventions: The Evolving Role of Registered Dietitian Nutritionists in Obesity Care
Gigliotti, Linda et al. Journal of the Academy of Nutrition and Dietetics

51


Next Step for KR – Question 4

KR is a 47yoM with type 2 diabetes x 5 years. Had recent stroke. A1C was 6.7% now increased to 8.2%. Not able to surf as much and gaining some weight. GFR 90+ and UACR less than 30mg/gm. What class of med would be best to start?


- A. SGLT-2i
- B. Biguanide - Metformin
- C. DPP-IV
- D. GLP-1 RA



52



53



54

Type 1 ~ Immune Mediated

5-10% of Diabetes

Screening is offered at no cost to eligible individuals to evaluate their personal risk of developing T1D. [See more](#)

DID YOU KNOW?

The risk for people in the general population (no T1D family history) is about 1 in 300. For those who have a family member with T1D, the risk is 1 in 20.

ADCEs In Practice - March 2024
Recent Advances in Type 1 Diabetes: Teplizumab (Tzield®)
Karen S. Fiano, PHARM.D., BCACP, Devada Singh-Franco, PHARM.D., CDCES, Young M. Kwon, BS, PH.D.

1.5 Million people have type 1 in U.S.

Prevalence increasing:

2001 – 1.48 per 1000 youths diagnosed with diabetes

2017 – 2.15 per 1000 youths diagnosed with diabetes

Incidence & Prevalence increasing

Highest incidence in Finland or Northern Europe.

58

Type 1 is 5- 10% of all Diabetes


- Auto-immune pancreatic beta cells destruction
- Most commonly expressed at age 10 – 14
- Insulin sensitive (require 0.5 - 1.0 units/kg/day)
- Expression due to a combo of genes and environment:
 - Autoimmunity tends to run in families
 - Exposure to virus or other environmental factors

59


Clinical onset of T1D can occur at any age

* A longitudinal study comprising 52,476 commercially insured Americans aged 0-64 years who developed T1D between 2005 and 2015. Rogers MM, et al. BMC Med. 2017;15(1):186.


60



61



62



63

Ordering Autoantibodies

AAbs are currently the only available serum immune marker to identify T1D prior to hyperglycemia and/or symptom onset

	GADA	IAA	IA-2A	ZnT8A	ICA	Blood draw location	Sampling method
Local laboratories (e.g. Quest, diagnostics, Labcorp)	✓	✓	✓	✓	✓	Local laboratory or healthcare provider's office	Blood draw
Online ordering, delivery to doctor's office	✓	✓	✓			Testing kits from vendors such as Enable Biosciences through online ordering	In-clinic finger poke blood test
TrailNet			✓	✓	✓	TrailNet-sponsored event, health fair, at-home kit (by mail)	Blood draw or at-home finger poke
Autoimmunity screening for kids	✓	✓	✓	✓		Barbra Davis Center, Children's Hospital Colorado, UC Health Laboratory, at-home kit (by mail)	Blood draw or at-home finger poke

Glutamic acid decarboxylase 65 autoantibody (GADA)
Insulin autoantibody (IAA)
Insulinoma-associated antigen 2 autoantibody (IA-2A)
Zinc transporter 8 autoantibody (ZnT8A)
Islet cell autoantibody (ICA)

64


Stages of T1D

	Stage 1	Stage 2	Stage 3
Characteristics	- Autoimmunity - Normoglycemia - Presymptomatic	- Autoimmunity - Dysglycemia - Presymptomatic	- Autoimmunity - Overt hyperglycemia - Symptomatic
Diagnostic criteria	2 or more islet autoantibodies - Glucose levels are in normal range - FBG <100mg/dL - A1C <5.6% 2-h PG <140mg/dL	2 or more islet autoantibodies - Dysglycemia: Elevated IFG and/or IGT - FPG 100–125 mg/dL 2-h PG 140–199 mg/dL - A1C 5.7–6.4% or ≥10% increase in A1C	- Autoantibodies may disappear over time (5–10% may not express antibodies) - Diabetes diagnosed by standard criteria


65

PHARMACOLOGIC INTERVENTION TO DELAY AND TREAT T1D: Key Data on Teplizumab-Tziel


THERAPY PROFILE: Teplizumab-Tziel



TRIAL DESIGN & PATIENT SELECTION



KEY EFFICACY DATA: DELAYING SYMPTOMATIC T1D



ADDITIONAL INFO

Herold KC, et al: Type 1 Diabetes TrialNet Study Group. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019 Aug 15;381(7):603-613.

FINANCIAL ASSISTANCE
Financial assistance available \$100,000 for treatment

FDA STATUS:
Teplizumab-Tziel (TZIELD) is FDA approved for Stage 2 AND Stage 3 Type 1 Diabetes.

66

Pharmacologic Intervention to Delay Stage 3 T1D

- ▶ Teplizumab-Tziel (CD3-monoclonal antibody)
- ▶ An option for individuals aged ≥ 1 years with stage 2 T1D to delay progression to Stage 3 T1D
- ▶ 14-day infusion for stage 2 T1D
- ▶ In a single trial, 44 individuals received 14-day course of teplizumab vs 32 in placebo
- ▶ The median time to delay stage 3 T1D was 2 years
 - ▶ 48.4 months in teplizumab group vs. 24.4 months placebo
- ▶ Financial assistance available

Herold KC, et al; Type 1 Diabetes TrialNet Study Group. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. *N Engl J Med.* 2019 Aug 15;381(7):603-613.

67

Templizumab for Stage 3 T1D

- ▶ An option for individuals aged 6-17 with stage 3 T1D diagnosed to delay the decline in endogenous insulin
- ▶ Must start within 8 weeks of diagnosis
- ▶ Requires 2, 12 day infusions, 6 months apart
- ▶ Patients treated with teplizumab (217 patients) had significantly higher stimulated C-peptide levels than patients receiving placebo (111 patients) at week 78 (95% CI, 0.09 to 0.17; $P < 0.001$)
- ▶ Caution: cytokine release syndrome, lymphopenia

TzielDNDP.com | For US Healthcare Providers
Ramos EL, et al; PROTECT Study Investigators. Teplizumab and β -Cell Function in Newly Diagnosed Type 1 Diabetes. *N Engl J Med.* 2023 Dec 7;389(23):2151-2161.

68

www.TrialNet.org

▶ How to get families linked to screening?

69

MJ Case Study

INITIAL DIAGNOSIS & MANAGEMENT

MJ is 65 years old

RECENT T2 DIABETES T2D

- PCP started MJ on Metformin; scheduled for 3-month follow-up.

LABORATORY RESULTS AT DIAGNOSIS

Fasting Glucose: 182
A1c: 8.2%

- At visit MJ reports has been implementing diet changes since initial diagnosis, "was sugar lover" and taking medications consistently.

MEDICAL HISTORY & RISK FACTORS

MEDICAL HISTORY

- hyperlipidemia
- hypothyroidism
- gastroesophageal reflux disease
- osteopenia
- h/o pacemaker placement
- recently diagnosed melanoma

KEY RISK & SOCIAL FACTORS

- Reports a strong family history of diabetes.
- Significant life stress over the previous year.

70

MJ Case Study: Medications

MEDICATION HISTORY & CURRENT REGIMEN

Medications: Metformin 1000 mg BID (Twice Daily) for past 3 months.

At time of referral (3-month follow-up), provider review

DECISION-MAKING FLOW

Provider prescribed initiation of new therapy based on accessible options.

SGLT2 inhibitor vs. GLP-1 AGONIST

SGLT2 inhibitor

\$400 copay

GLP-1 AGONIST

Financially Inaccessible

ADDITIONAL MEDICATIONS & PLAN

OTHER PRESCRIBED MEDICATIONS

- rosuvastatin 10 mg,
- omeprazole 40 mg capsule,
- levothyroxine 100 mcg tab,
- Vitamin D 2000 IU

71

Physical and Labs

Anthropometric Data

Height: 5 ft 7 in

Weight: 125 lb (56.8 kg)

Usual body weight: 130–134 lb

Laboratory Results

Labs: 1 week prior to visit

Hemoglobin A1c: 10.0%

Glucose: 263 mg/dL

- Total cholesterol: 168 mg/dL
- HDL: 74 mg/dL
- LDL: 70 mg/dL
- Triglycerides: 120 mg/dL

72

Questions

- ▶ What labs do you want to draw to determine if right diagnosis?
- ▶ What change in therapy?
- ▶ If you were starting MJ on insulin, what would be the dose?
- ▶ What medical nutrition therapy would you recommend?
- ▶ Are there any concerns with the current treatment plan?



73

Questions & Answers

- ▶ What labs do you want to draw to determine if right diagnosis?
- ▶ What change in therapy?
- ▶ If you were starting MJ on insulin, what would be the dose?
- ▶ What medical nutrition therapy would you recommend?
- ▶ Are there any concerns with the current treatment plan?



74

Type 1 Diabetes Features?



- ▶ For JR, a 28 admitted to the ICU with a blood glucose of 476 mg/dl, pH of 7.1, anion gap of 15. Recently lost 13 pounds.

Type 1 Most Discriminative Features


- Younger than 35 years at diagnosis
- Lower BMI (<25 kg/m²)
- Unintentional weight loss
- Ketoacidosis
- Glucose 360 mg/dl or greater.

Misdiagnosis is common and can occur in ~40% of adults with new type 1 diabetes



75

Standard 4 – Comprehensive Medical Evaluation & Assessment



Standards of Care in Diabetes—2026



76

4. Comprehensive Medical Evaluation and Assessment of Comorbidities

- ▶ Use person-centered communication, culturally sensitive, strength-based language and active listening;
- ▶ Elicit individual preferences and beliefs; develop self-management plan together.
- ▶ Diabetes Care coordinated by multi disciplinary team:
 - ▶ CDCES, Providers, nurses, dietitians, exercise specialists, pharmacists, dentists, podiatrists, and behavioral health professionals.
- ▶ Goal is to optimize health outcomes and health-related quality of life.



4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2026

77

Communication Goals

- ▶ The communication goal between health care professionals and people with diabetes is to:
- ▶ Establish a collaborative relationship.
- ▶ Assess and address self-management barriers *without* blaming people with diabetes for “noncompliance” or “nonadherence”
 - ▶ when the outcomes of self-management are not optimal.



4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2026

78

Language Guidelines – 5 Key Points


- ▶ Use language that is:
 - ▶ **Neutral, nonjudgmental**, and based on facts, actions, physiology, or biology.
 - ▶ **Free from stigma**.
 - ▶ **Strength based**, respectful, and inclusive, imparts hope.
 - ▶ **Fosters Collaboration** between people with diabetes and health care professionals.
 - ▶ **Person centered**



79

Create a Judgement Free Zone – Roll out the Carpet of Acceptance

There are no bad or good blood glucose numbers.
 There is no such thing as cheating.
 You are not failing at your diabetes.
 It is not your fault you have diabetes.
 Thank you for showing up today.



80

Cultural Humility



Cultural humility is an active, self-reflective, lifelong practice involving continuous exploration of our own and others' cultural identities and beliefs;

- an awareness of one's own biases and background;
- treating others with respect, openness, and empathy;
- and reducing power imbalances within relationships and communities.

Cultural humility is a key ingredient in building relationships and partnerships of trust.

<https://cahealthadvocates.org/cultural-humility-what-is-it-why-it-matters/>

81

Self Reflective Question

- ▶ A person shows up to appointment, and tells you they are only taking their daily insulin injection about 4 times a week.
- ▶ What feelings would that evoke?



curiosity

Use OARS
Method to explore
further.

82

OARS Communication Framework

- ▶ Open-ended Questions: 'What concerns you most?'
- ▶ Affirmations: 'You've worked hard.'
- ▶ Reflective Listening: 'This feels exhausting.'
- ▶ Summaries: 'Let me summarize...'



83

What Matters Most to YOU?

What Matters Most – Structured Tool
It is important to make health decisions that line up with your priorities, especially when you have many medical concerns. To do so, it is important to know what matters most to you. For some, this can be hard to put into words. This tool may help.

Circle up to 3 things in each column that MATTER MOST to you.

FUNCTIONING	ENJOYING LIFE	CONNECTING
• Think clearly • Walk or move around by myself • Choose where I live • Eat foods I enjoy • Work or volunteer • Make decisions about my finances • Dress or bathe myself • Be able to see (or hear, smell, taste, touch) • Drive or be able to get around outside my home • Other:	• Participate in favorite hobbies (like sports, gardening, woodworking, reading, art, etc.) • Attend social events (like movies, concerts, parties, meetings, etc.) • Participate in religious/spiritual services or practices • Spend time outdoors or connecting to nature • Do things to improve myself, learn, or be creative • Have physical touch and / or sexual intimacy • Have quiet time doing nothing in particular • Travel and/or see new places • Exercise • Other:	• Spend time with family and friends • Have good relationships with family or friends • Connect to God or a higher power • Avoid being a burden to others • Take care of my pet(s) • Feel connected to positive aspects of myself • Contribute to my community or neighborhood • Take care of family or friends (like being a caregiver) • Other:

Of all the things you circled, Which 3 Matter Most above all? (Put an X next to them).
In your own words, what do they mean to you?

Moye J, Driver JA, Owlsamy MT, Chen LQ, Whitley JC, Auguste EJ, Paik JM. Assessing What Matters Most in Older Adults With Multicomplexity. Gerontologist. 2022 Apr 20;62(4):e224-e234. doi: 10.1093/geront/gnab071. PMID: 34043004; PMCID: PMC8982330.

84

Our Curiosity Makes a Difference

What is something you would like me to know about you?

EXPERTISE IN ACTION | #ADCES26

85

Diabetes Goals and Treatment Plan

The goals of treatment for diabetes are to prevent or delay complications and optimize quality of life.

Goals and plans co-created by the care team and individual based on preferences, values, and goals.

Management plan considers the person's:

- Age, cognitive abilities, school/work schedule and conditions.
- Health beliefs, support systems, social situation, financial concerns, cultural factors, literacy and numeracy.
- Eating patterns, physical activity, (metformin/fatigue)
- Diabetes history (duration, complications, and current use of medications), comorbidities, disabilities, health priorities, other medical conditions.
- Preferences for care, access to health care services, and life expectancy.

4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2024

86

ADA 2026 ABC Goal Summary

A1c less than 7% (individualize)

- Pre-meal BG 80-130
- Post meal BG <180
- Time in Range (70-180) 70% of time

Blood Pressure

<130/80
<120/80 for high risk

Cholesterol

- Statin therapy based on age & risk status
- If 40+ with ASCVD Risk, decrease LDL by 50%, LDL <70
- If 40+ with ASCVD, decrease LDL by 50%, LDL <55

87

ADA – Complete Medical Evaluation

- ▶ Review, confirm diabetes diagnosis
- ▶ Assess glycemic status
- ▶ Eval for diabetes complications/ health status
- ▶ ID care partners, support systems
- ▶ Investigate co-conditions, overall health status
- ▶ Assess Social Determinants of Health (SDOH) & Barriers
- ▶ Review risk factor mgmt.
- ▶ Collaborate on plan of care



4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2026

88

Case Study - JR

- ▶ 38 yr old, BMI 24.3, arrives in clinic for physical. Says has been feeling tired lately, but attributes that to the job. In office fingerstick reads 228 mg/dl.
- ▶ 1. What lab tests are needed?
- ▶ 2. What would you include in your physical exam?
- ▶ What vaccinations?
- ▶ What referrals?
- ▶ What tools?



89

Lab Eval at Initial & Annual Visit

- | | |
|--|---|
| <ul style="list-style-type: none"> ▶ A1c (each 3-6 mo's) ▶ Each year <ul style="list-style-type: none"> ▶ Lipids, CBC with platelets ▶ Liver function ▶ Spot urinary albumin-to-creatinine ratio (UACR) ▶ Serum creat and GFR ▶ TSH, celiac (type 1) ▶ B12 if on metformin >5yrs ▶ Calcium, Vita D, and phosphorus if appropriate | <ul style="list-style-type: none"> ▶ Serum K <ul style="list-style-type: none"> ▶ If on ACE, ARBs or diuretics |
|--|---|



4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2026

90

Case Study - JR

- ▶ 38 yr old, BMI 24.3, arrives in clinic for physical. Says has been feeling tired lately, but attributes that to the job. In office fingerstick reads 228 mg/dl.
- ▶ 1. What lab tests are needed?
- ▶ 2. What would you include in your initial exam?
- ▶ What vaccinations?
- ▶ What referrals?
- ▶ What tools?



91

Physical Exam

- ▶ Height, weight, BMI, pubertal development
- ▶ Blood pressure
- ▶ Fundoscopic exam, thyroid
- ▶ Skin exam –insertion sites, acanthosis, fungus, sores, feet
- ▶ Bone health, Hypo
- ▶ Depression, Distress Anxiety
- ▶ Functional and cognitive issues
- ▶ Reproductive history
- ▶ Comprehensive foot exam
 - ▶ Visual eval
 - ▶ Screen for Peripheral Arterial Disease
 - ▶ Monofilament and vibration assessment



4. Comprehensive Medical Evaluation and Assessment of Complications: Standards of Care in Diabetes—2024

92

Table 4.1—Components of the comprehensive diabetes medical evaluation at initial, follow-up, and annual visits

	Visit		
	Initial	Every follow-up	Annual
Past medical and family history			
Diabetes history			
• Characteristics at onset (e.g., age and symptoms and/or signs)	✓		
• Review of previous treatment plans and response	✓		
• Assess frequency, cause, and severity of past hospitalizations	✓		
Family history			
• Family history of diabetes in a first-degree relative	✓		
• Family history of autoimmune disorders	✓		
Personal history of complications and common comorbidities			
• Common comorbidities (e.g., obesity, OSA, and MASLD)	✓		✓
• High blood pressure or abnormal lipids	✓	✓	✓
• Macrovascular and microvascular complications	✓	✓	✓
• Hypoglycemic awareness, frequency, cause, and timing of episodes	✓	✓	✓
• Presence of hemoglobinopathies or anemias	✓	✓	✓
• Last dental visit	✓	✓	✓
• Last foot exam	✓	✓	✓
• Last dilated eye exam	✓	✓	✓
• Visits to specialists	✓	✓	✓
Disability assessment and use of assistive devices (e.g., physical, cognitive, vision and auditory, history of fractures, and podiatry)	✓	✓	✓
Personal history of autoimmune disease	✓		
Surgical and procedure history			
• Surgeries (e.g., metabolic surgery and transplantation)	✓	✓	✓
Interval history			
• Changes in medical or family history since last visit	✓	✓	✓
Behavioral factors			
• Physical activity, sleep behaviors, eating patterns and weight history	✓	✓	✓
• Assess familiarity with carbohydrate counting (e.g., type 1 diabetes or type 2 diabetes treated with MDI)	✓	✓	✓
• Screen for OSA	✓	✓	✓
• Tobacco, alcohol, and substance use	✓	✓	✓
Medications and vaccinations			
• Current medication plan	✓	✓	✓
• Medication-taking behavior, including rationing of medications and/or medical equipment	✓	✓	✓

Standard 4 – Diabetes Medical Evaluation

Table 4.1—Components of the comprehensive diabetes medical evaluation at initial, follow-up, and annual visits

	Initial	Every follow-up	Annual
Laboratory evaluation			
• A1C, if the results are not available within the past 3 months or if earlier assessment is necessary	✓	✓	✓
• Lipid profile, including total, LDL, and HDL cholesterol and triglycerides	✓	✓	✓
• Liver function tests (i.e., ALT, AST, ALP, and GGT)	✓	✓	✓
• Spot urinary albumin-to-creatinine ratio	✓	✓	✓
• Serum creatinine and estimated glomerular filtration rate(s)	✓	✓	✓
• Thyroid-stimulating hormone in people with type 1 diabetes	✓	✓	✓
• Cellular disease screening in people with type 1 diabetes	✓	✓	✓
• Vitamin B12 if taking metformin for >5 years	✓	✓	✓
• CAC with plaques	✓	✓	✓
• Serum potassium levels in people treated with ACE inhibitors, ARBs, or diuretics	✓	✓	✓
• Calcium, vitamin D, and phosphorus as appropriate	✓	✓	✓

4. Comprehensive Medical Evaluation and Assessment of Complications: Standards of Care in Diabetes—2024

93

Lab Test, BP, Family History

- ▶ A1C – 9.8%
- ▶ Cholesterol - 216
- ▶ LDL – 164 mg/dL
- ▶ HDL – 46
- ▶ Triglycerides – 276
- ▶ TSH – 1.43
- ▶ GFR - >60
- ▶ UACR - <30 mg/gm
- ▶ ALT, AST 20 & 27
- ▶ Platelets 217
- ▶ K+ 3.8
- ▶ Family history
 - ▶ Dad with type 2, history of stroke
- ▶ B/P
 - ▶ 156/88 then 148/82
- ▶ BMI 24.3
- ▶ Skin – some acanthosis nigricans visible on neck
- ▶ Lower extremities okay
- ▶ Mouth - gingivitis

94

Acanthosis Nigricans




- ▶ A skin disorder characterized by darkening (hyperpigmentation) and thickening (hyperkeratosis) of the skin
- ▶ mainly in the folds of the skin in the armpit (axilla), groin and back of the neck.
- ▶ Acanthosis nigricans is not a skin disease per se but a cutaneous sign of an underlying condition or disease.
- ▶ Associated with extra weight and insulin resistance

95

Medical Evaluation Goal

- ▶ Assess:
 - ▶ Diabetes self-management, nutrition, psychosocial health, risk of acute and chronic complications
 - ▶ Sleep habits
 - ▶ Cancer screenings
 - ▶ Bone Health
 - ▶ Liver Health
 - ▶ Cardiovascular disease
 - ▶ Reproductive and Sexual Health
 - ▶ Smoking cessation
 - ▶ Ophthalmological, dental and podiatric referrals



© Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2024

96

Case Study - JR

- ▶ 38 yr old, BMI 24.3, arrives in clinic for physical and **wonders why she can't get pregnant**. Says has been feeling tired lately, but attributes that to the job. In office fingerstick reads 228 mg/dl.
- ▶ 1. What lab tests are needed?
- ▶ 2. What would you include in your initial exam?
- ▶ **What referrals?**
- ▶ What tools?



97

Referrals for Initial Care Mgmt

What is the Priority for JR?

- ✓ Eye professional – annual check
- ✓ RD for nutrition therapy
- ✓ DSMES - Diabetes Self-Management Education Support
- ✓ Dentist for comprehensive dental examination
- ✓ Women's health specialist
- ▶ Behavioral health professional & audiology, if indicated
- ▶ Social worker/community resources
- ▶ Rehab medicine for cog/disability eval




4. Comprehensive Medical Evaluation and Assessment of Complications: Standards of Care in Diabetes—2024


98

PCOS to PMOS

CLINICAL FEATURES OF POLYENDOCRINE METABOLIC OVARIAN SYNDROME (PMOS)



99



100

Treatment for PMOS

- Lifestyle interventions** – activity, nutritious foods, adequate sleep, and stress management
- Medications**
 - Metformin
 - GLP-1 receptor agonists or dual GIP/GLP-1 therapies.
 - Combined hormonal contraceptives can help regulate menstrual cycles and reduce symptoms of androgen excess
 - Spironolactone may be prescribed for acne or excess hair growth.

Many people with PMOS spend years seeking answers before receiving a diagnosis.

Not everyone with PMOS has overweight or obesity.

Up to 20–30% of individuals may have a normal BMI yet still experience insulin resistance, androgen excess, ovulatory dysfunction, or cardiometabolic risk.

101

GLP-1 Receptor Agonists and Reproductive Health

Implications for Contraception, Fertility, and Pregnancy

Florence Porterfield, MD¹, Jennifer Mulligan, MD², Katherine Salim, MD³, Olayemi Oubowale, MD, MS⁴, Fatima Cody Stanford, MD, MPH, MSW, MSc, MEd, MHS, MPP^{5,6,7,8,9}


- In women with PMOS, GLP-1 RAs improve metabolic and endocrine parameters, including
 - reductions in androgen levels and
 - increases in sex- hormone binding globulin, which may contribute to improved menstrual regularity
- GLP-1 RAs are increasingly used during reproductive age, making their effects on contraception, reproductive physiology, fertility, and pregnancy an important emerging clinical consideration.
- Evidence regarding fertility outcomes and pregnancy safety remains limited, highlighting the need for prospective studies to guide counseling on GLP-1 RA use in reproductive-aged individuals.

Endocrine Metab Clin N Am • 2020 • 15(1) • 1-10
Copyright © 2020 Elsevier Inc. All rights reserved. Including those for text and data mining, AI training, and similar technologies.

102

Medical Nutrition Therapy Works

- ▶ MNT is effective and beneficial to people with prediabetes and diabetes.
- ▶ When delivered by an RDN, MNT is associated with A1C absolute decreases of:
 - ▶ 1.0–1.9% for people with type 1 diabetes and
 - ▶ 0.3–2.0% for people with type 2 diabetes



Copyright © 2019 | December 18, 2019
5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes—2019

103

JR Returns in 1 month

- ▶ Blood glucose improved
- ▶ B/P 142/94 Pulse 86
- ▶ Meds started include:
 - ▶ Metformin 1000 mg
 - ▶ Glipizide 10 mg BID (sulfonylurea)
 - ▶ Lovastatin 40 mg
 - ▶ Lisinopril 20mg (ACE Inhibitor)
 - ▶ Spironolactone 50mg
- ▶ JR checks BG 4-7 x's a week.
 - ▶ Lowest 152, Highest 289
- ▶ What other issues do we need to evaluate?
 - ▶ Activity – mostly sedentary
 - ▶ Sleep: 6-7 hrs a night
 - ▶ Brushing – once daily
 - ▶ Alcohol and other drug use
 - ▶ Drinks a glass of wine with dinner
 - ▶ Coping – had appt with women's health specialist – has PMOS
 - ▶ Affordability
 - ▶ Met with CDCES and RDN
 - ▶ Has appt with Eye doctor and dentist

Provider increases
metformin/glipizide and adds
SGLT-2 Empagliflozin 10 mg

104

JR's Question

- ▶ Does diabetes cause complications?
 - ▶ Yes
 - ▶ No, not always

Let's get JR in to get
Eyes and Teeth
Evaluated




105

Eye Disease Overview

- ▶ Diabetes retinopathy - leading cause of adult blindness.

- ▶ Factors that increase risk / co-associated:

- ▶ Chronic hyperglycemia
- ▶ Nephropathy
- ▶ Hypertension
- ▶ Dyslipidemia




People with diabetes also have more glaucoma, cataracts and other eye disorders earlier and more frequently.

106


Eye Disease and Education

- ▶ Diabetes Retinopathy
- ▶ Other Diabetes Eye Complications
- ▶ Prevention and Treatment
- ▶ Promoting Self-Care



107

Fundus Geography



The retina is the only portion of the central nervous system visible from the exterior. Likewise the fundus is the only location where vasculature can be visualized.

Funduscopy

108

What is Retinopathy?

- ▶ Retina – layer of nerve tissue in back of eye responsible for processing images and light
- ▶ Damage to the microvascular layer that nourishes the retina
- ▶ Leads to leakage of blood components through vessel walls and creation of **unstable blood vessels due to hypoxia**
- ▶ Disturbance in nerve layer = visual symptoms



109


Non Proliferative



Dilated capillaries (microaneurysms) leak red blood cells and plasma into retina. Results in retinal hemorrhages, edema and deposits (exudates).

110

Non-Proliferative to Proliferative Diabetic Retinopathy



Treatment is effective at slowing progression. Development of severe diabetic retinopathy happens over years or decades.


*Note: Clinical details are illustrative. Consult a professional for diagnosis.

ADAM

111

Proliferative retinopathy

new blood vessel formation on surface of retina or the optic nerve. Severe visual loss can occur due to vitreous hemorrhage and retinal detachment. Note fine network of new blood vessels on the surface of the optic nerve



112

Proliferative Diabetic Retinopathy (PDR)

- ▶ Clinical Findings
 - ▶ Ischemia induced neovascularization
 - ▶ at the optic disk (NVD)
 - ▶ elsewhere in the retina (NVE)
 - ▶ Vitreous hemorrhage
 - ▶ Retinal traction, tears, and detachment
 - ▶ Diabetes Macular Edema must also be evaluated



113

PDR Signs

Blurred central or side vision (left, blurred side vision) or a blind spot in central vision (right) may indicate diabetic retinopathy



114

Retinopathy Changes How We See



View of boys by person with healthy vision



View of boys by person with diabetic retinopathy.

115

Quick question 6

► Which of the following is a recommended treatment for proliferative retinopathy?

- A. Vitamin E supplements
- B. Laser phototherapy
- C. Anti-Vascular Endothelial Growth Factor
- D. Both B and C

qu?z

116

Pan Retinal Photocoagulation



Decreases risk of severe vision loss by 50% or more
Destroys 12% of retina and loss of visual field.
Once stabilized, can achieve excellent control of PDR if B/P and BG well controlled.

117

PDR Management

- ▶ Management/Treatment
 - ▶ 2-4 month follow-up
- ▶ Treatment includes:
 - ▶ Laser therapy or
 - ▶ Anti-Vascular Endothelial Growth Factor (Anti- VEGF) eye injections
- ▶ Vitrectomy if bleeding into vitreous

118

12. Microvascular Complications - Eyes

- ▶ Optimize BG and B/P Control to protect eyes
- ▶ Screen with initial dilated and comprehensive eye exam by ophthalmologist or optometrist
 - ▶ Type 2 at diagnosis, then every year*
 - ▶ Type 1 within 5 years of dx, then every year*
- ▶ *If **no** evidence of retinopathy **and** glycemic indicators within goal range, then screening every 1–2 years may be considered.




119

High Quality Fundus Photography to Screen for Retinopathy

Can detect most clinically significant diabetic retinopathy.

- ▶ Serves as screening tool for retinopathy, not substitute for comprehensive eye exam
- ▶ Appropriate to use retinal photography with remote reading or U.S. FDA of approved [artificial intelligence algorithms](#) to improve access to diabetes retinopathy screening.
- ▶ Refer for comprehensive in-person eye exam when indicated.



120

Sexual and Dental Health

- ▶ Screen for those with prediabetes and diabetes for **sexual dysfunction**.
- ▶ Men – erectile dysfunction and level of libido
- ▶ **Dental health**
- ▶ Coordinate efforts between medical and dental teams.
- ▶ Refer for dental exam at least once a year.
- ▶ Treatment can lower A1C 0.4%



4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Guidelines for Diabetes

121

Poll Question 7

- ▶ Diabetes is associated with an increased risk of oral disease. Which of the following statements is true for people with diabetes?
- a. Benefit from vinegar gargles to decrease bacterial load
- b. At greater risk for tongue cancer.
- c. 1 in 5 cases of tooth loss is linked to diabetes
- d. Diabetes is associated with increased tonsillitis.

122


Periodontal Disease

- ▶ More severe and prevalent with diabetes and elevated A1C levels.

- ▶ periodontal treatment associated with better glycemic control (A1C 8.3% vs. 7.8%)
- ▶ Benefits lasted for 12 mo's

- ▶ People with periodontal disease have higher rates of diabetes.

- ▶ First time, periodontal disease is listed as a risk factor for diabetes in ADA Std's.



Oral Care Matters

- See dentist at least yearly
- Dental hygienist twice yearly
- Brush twice daily
- Floss daily

123

Gingivitis




124

Mild to Severe Periodontitis



125

Periodontal disease and Heart Disease



- Heart disease link:
 - oral bacteria enter the blood stream, attach to fatty plaques in coronary arteries increasing clot formation
 - inflammation increases plaque build up, which may contribute to arterial inflammation
- Hyperglycemia = Gingivitis = Heart Disease

126

Keeping Oral Healthy

- ▶ Oral disease linked with heart disease
- ▶ Dental exams (every 6 mo's)
- ▶ Metabolic control critical
- ▶ Quit smoking
- ▶ Brush twice daily and floss daily.
- ▶ Help access affordable dental care.



Best \$10 investment

127

Bone Health & Other Issues

128

Fractures

- ▶ Hip fractures:
 - ▶ Type 1 - 4.3 relative risk associated w/ osteoporosis
 - ▶ Type 2 – 1.8 relative risk
- ▶ Health care professionals can:
 - ▶ Assess risk fracture risk and history, esp with older clients
 - ▶ Recommend bone mineral density assessment
 - ▶ Assess if would benefit from vita d supplement
 - ▶ Home health/ Physical Therapy
 - ▶ Use TZDs and SGLT's with caution



4. Comprehensive Medical Evaluation and Assessment of Complications: Standards of Care in Diabetes—2019, 409

129

Bone Mineral Density Testing

- Determination of fracture risk traditionally relied on measurements of bone mineral density (BMD) and the World Health Organization–defined T-score of less than -2.5 SD.
- Now established that the consideration of other risk factors improves the categorization of fracture risk



4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2026

If at Risk for Fracture - Advise people with diabetes on their intake of calcium (1,000–1,200 mg/day) and vitamin D to ensure it meets the recommended daily allowance through their diet or supplemental means.

130

Assess Risk factors for Fracture

Table 4.4—Diagnostic assessment

Individuals who should receive BMD testing

People aged ≥ 65 years

Postmenopausal women and men aged ≥ 50 years with history of adult-age fracture or with diabetes-specific risk factors:

- Frequent hypoglycemic events
- Diabetes duration >10 years
- Diabetes medications: insulin, thiazolidinediones, sulfonylureas
- A1C $>8\%$
- Peripheral or autonomic neuropathy, retinopathy, nephropathy
- Frequent falls
- Glucocorticoid use

Avoid TZDs if high risk and use caution with medications that can cause hypo (insulin, meglitinides and sulfonylureas)

4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2026

131

Obstructive Sleep Apnea - OSA

- OSA affects ~25% of people with type 2
 - Up to 60% of those with type 2 have disordered sleep
- Associated with increased CVD risk
- Signs include excessive daytime sleepiness, snoring and witnessed apnea
- Treatment:
 - Lifestyle modification
 - Tirzepatide (Zepbound)
 - Continuous positive oral airway pressure and devices
 - Surgery



4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2026

132

Sexual Functions as We Age

- ▶ 20-30 years trice daily
- ▶ 30-40 years tri weekly
- ▶ 40-50 years try weekly
- ▶ 50-60 years try weakly
- ▶ 60-70 years try oysters
- ▶ 70-80 years try anything
- ▶ 80-90 years try to remember



133

Women with Diabetes & Sexual Health

- ▶ Screening for desire (libido), arousal, and orgasm difficulties, particularly in those who experience depression and/or anxiety and those with recurrent urinary tract infections
- ▶ In postmenopausal women, screen for symptoms and/or signs of genitourinary syndrome of menopause, including vaginal dryness and dyspareunia.



4. Comprehensive Medical Evaluation and Assessment of Complications: Standards of Care in Diabetes—2024

134

Assess Sexual Health

- ▶ In women with diabetes or prediabetes, assess sexual health:
- ▶ 33% reported female sexual dysfunction (FSD)
- ▶ Screen for desire (libido), arousal, orgasm difficulties, particularly in those with depression and/or anxiety and those with recurrent urinary tract infections.
- ▶ In postmenopausal women - screen for symptoms and/or signs of genitourinary syndrome of menopause, including vaginal dryness and dyspareunia.



135

Improving Sex Life

People with diabetes get more vaginal and bladder infections

- ▶ Difficulty achieving orgasm due to neuropathy
- ▶ Painful intercourse due to lack of vaginal lubrication



Treatment

- ▶ Lower blood glucose / blood pressure
- ▶ Treat vaginal infections and UTI's
- ▶ Water based lubricants for vaginal dryness
- ▶ Hormone replacement therapy
- ▶ Eat to prevent lows during intimacy
- ▶ Allow time, touching and romance

Many people with diabetes have issues with sexual desire, arousal, or orgasm. How about you?"

136

Erectile Dysfunction


- ▶ Affects about 50% of men with diabetes
- ▶ Loss of erections sufficient for intercourse
- ▶ Due to combo of vascular and nerve damage
- ▶ Address BG, BP, smoking and other factors
- ▶ Tests: penile tumescence to eval if organic or psychogenic
- ▶ Treatment:
 - ▶ Sildenafil (Viagra), Vardenafil (Levitra), Tadalafil (Cialis)
 - ▶ Use caution if taking nitrate drugs. Check w/ MD first
 - ▶ Other meds, vacuum devices, prosthetics
 - ▶ HRT- testosterone gel, patches, injections, pills



137

Men with Diabetes 2x's risk for low testosterone

- ▶ Symptoms include low sex drive, ED, depression, lack of energy and vitality
- ▶ Low T easily diagnosed and managed, only 10% of men currently treated
- ▶ Initial Screening:
 - ▶ Total testosterone: if < 300 ng/dl = hypogonadal
 - ▶ am testing preferred, repeat to confirm
- ▶ Treatment: determine cause, testosterone replacement therapy



138

JR Return Visit 6 months

- ▶ A1c 7.3% (was 8.6)
- ▶ TSH 1.9 mIU/L
- ▶ B/P 132/82 Pulse 76
- ▶ Started CGM
 - ▶ TIR 68%
 - ▶ TBR 6% (mostly overnight)
- ▶ Walking after dinner.
- ▶ Saw dentist & eye doctor
- ▶ Sometimes forgets to take meds at night
- ▶ Sleeping better
- ▶ Worried if meds are causing harm
- ▶ Using contraception

Meds include:

- ▶ Metformin 2000 mg
- ▶ Empagliflozin 25 mg
- ▶ Glipizide 20 mg BID
- ▶ Lovastatin 40 mg
- ▶ Lisinopril 40mg
- ▶ Spironolactone 50 BID
- ▶ 10 units basal insulin

Provider increased lisinopril & empagliflozin to 25mg and added 10 units basal insulin
Would you suggest a different approach?



139

Diabetes Toolkit - Individualize

- Meter/CGM**
 - ▶ BG Checks and logging results
- List of Meds**
 - ▶ Diabetes ID
- Meals & Snacks**
 - ▶ Phone, medic alert, on person
- When to Get Help**
 - ▶ Carbohydrate source
- Emotional Support**
 - ▶ Granola bar, glucose tabs, GU, gummy bears
 - ▶ Rescue Meds

140


Poll Question 8

In the 2026 ADA Standards they recommend pharmacologic agents along with lifestyle interventions to treat people with diabetes and Metabolic Associated Steatohepatitis (MASH). Which of the following are the recommended diabetes medications to treat MASH?

- A. Vitamin E and SGLT-2
- B. Pioglitazone and/or GLP-1 RA / GIP
- C. Fish oil supplements and statin
- D. Metformin and/or bolus insulin therapy



141



Liver Disease: MASLD or MASH

- In adults with T2D, MASLD and overweight/obesity, consider using a GLP-1 RA with demonstrated benefits in MASH or a GLP-1/GIP RA with potential benefits for MASH
- In adults with biopsy proven MASH, GLP-1 RA is preferred.
- Pioglitazone or a dual GIP/GLP-1 RA can be considered for glycemic management due to potential beneficial effects on MASH.
- Insulin preferred for decompensated cirrhosis

Semaglutide
Tirzepatide
Pioglitazone

Insulin Sensitizers

- ▶ **Action:** decrease insulin resistance by making muscle and adipose cells more sensitive to insulin, decrease free fatty acids
- ▶ **Name:**
 - ▶ pioglitazone (Actos) – bladder cancer warning
 - ▶ Dosing: 15-45 mg daily
 - ▶ Consider adding low dose if history of stroke or have steatosis
- ▶ **Efficacy/ Considerations**
 - ▶ Reduce A1C ~0.5-1.0%
 - ▶ 6 weeks for maximum effect
 - ▶ pioglitazone \$5 a month
 - ▶ Can cause fluid retention, not indicated w/ CHF



Thiazolidinediones "TZD" • Increases insulin sensitivity	pioglitazone (Actos) 15 – 45 mg daily	Pioglitazone is recommended for people with diabetes after a stroke and/or to treat steatosis. May increase bladder cancer risk. Start with low dose, increase if needed. Monitor for edema. Increases fracture risk. Lowers A1C 0.5 – 1.0%.
---	--	--

Case Study LS

LS is 69 with type 2 diabetes for over a decade. Takes metformin 1000mg twice daily. **Admitted to hospital with heart failure.**

A1C=7.3%.

UACR 212mg/gm

eGFR=56

B/P 146/82

What class of diabetes med do we need to start ASAP?

Albuminuria Categories	Urinary Albumin Creatine Ratio (UACR)
Normal to mildly increased – A1	< 30 mg/g
Moderately increased – A2	30 – 299 mg/g
Severely increased – A3	300 mg/g +
Kidney Disease Stage	GFR
Stage 1 – Normal	90+
Stage 2 – Mild loss	89 - 60
Stage 3a – Mild to Mod	59 - 45
Stage 3b – Mod to Severe	44 - 30
Stage 4 – Severe loss	29 - 15
Stage 5 – Kidney failure	14 - 0

148

SGLT2 Inhibitors- “Glucoretics”


- **Action:** decreases renal reabsorption of glucose proximal tubule of kidneys (reset renal threshold)
- **Preferred** diabetes treatment for people with heart and kidney failure. Decreases BG & CV Risk.
- AWP: ~\$650 a month




Class/Main Action	Name(s)	Daily Dose Range	Considerations
SGLT2 Inhibitors “Glucretic” • Decreases glucose reabsorption in kidneys	Canagliflozin** (Invokana)	100 - 300 mg 1x daily	Side effects: hypotension, UTIs, genital infections, increased urination, weight loss, ketoacidosis. Heart Failure, CV & Kidney Protection: 1st line therapy for Heart Failure (HF), Kidney Disease (CKD), Cardiovascular Disease, before or with metformin. Considerations: If GFR ≥ 20, use SGLT-2 to reduce CVD, Heart Failure and Chronic Kidney Disease. Limited BG lowering effect if GFR <45. See package insert for GFR cut-offs and dosing. Benefits: SGLT-2s* reduce BG, CV death & HF, slow CKD. *Approved for peds, 10 yrs +. Lowers A1C 0.6% to 1.5%.
	Dapagliflozin** (Farxiga)	5 - 10 mg 1x daily	
	Empagliflozin** (Jardiance)	10 - 25 mg 1x daily	
	Ertugliflozin (Steglatro)	5 - 15 mg 1x daily	
	Bexagliflozin (Brenzavvy)	20 mg 1x daily	

149


Use of Glucose-Lowering Medications in the Management of Type 2 Diabetes




150



151



152



153

New in 2026: GLP-1 in Kidney Disease

- In adults with T2D and advanced CKD (eGFR <30), a GLP-1 RA is preferred for glycemic management due to lower risk of hypoglycemia and for CV event reduction.
- Individuals on dialysis can be safely initiated or continued on GLP-1 based therapy to reduce CV risk and mortality
- Reminder: only GLP-1 with renal restrictions are exenatide and lixisenatide



From: 8. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026

154

SGLT-2 Inhibitor Indications

Drug	Lowers BG	CV Indication	Heart Failure Indication	Kidney Indication
Dapagliflozin (Farxiga)	Yes for 10 yrs and older	Yes	Yes +/- Diabetes	Yes +/- Diabetes
Empagliflozin (Jardiance)	Yes for 10 yrs and older	Yes	Yes +/- Diabetes	Yes +/- Diabetes
Canagliflozin (Invokana)	Yes for 10 yrs and older	Yes	Yes w/ Diabetes	Yes w/ Diabetes
Ertugliflozin (Steglatro)	Yes	No	No, although showed benefit	No
Bexagliflozin (Brenzavvy)	Yes	No	No	No

155

Poll Question 8

► JR, a 67-year-old with type 2 diabetes for 7 years, with an A1C of 9.7% was started on empagliflozin 10mg two weeks ago. Other labs include a GFR of 49 and a UACR of 34 mg/g. Also takes glargine 12 units and pioglitazone. JR drinks a few beers at night. Partner calls you in a panic and says JR is admitted to the hospital in DKA. What is the most likely explanation?

- Excess alcohol intake leading to starvation ketosis
- Potential side effect of SGLT-2 Inhibitors
- Low GFR and elevated UACR increase hyperglycemic risk
- JR is misdiagnosed and likely has type 1 diabetes



156

SGLT-2 Inhibitors – DKA Warning

Common Oral Diabetes Meds

Class/Main Action	Name(s)	Daily Dose Range	Considerations
SGLT2 Inhibitors "Glucoretic" • Decreases glucose reabsorption in kidneys	Canagliflozin* (Invokana)	100 - 300 mg 1x daily	Side effects: hypotension, UTIs, genital infections, increased urination, weight loss, ketoacidosis. Heart Failure, CV & Kidney Protection: 1st line therapy for Heart Failure (HF), Kidney Disease (CKD), Cardiovascular Disease, before or with metformin Considerations: If GFR ≥ 20, use SGLT-2 to reduce CVD, Heart Failure and Chronic Kidney Disease. Limited BG lowering effect if GFR <45. See package insert for GFR cut-offs and dosing. Benefits: SGLT-2s* reduce BG, CV death & HF, slow CKD. *Approved for peds, 10 yrs +. Lowers A1C 0.6% to 1.5%.
	Dapagliflozin** (Farigla)	5 - 10 mg 1x daily	
	Empagliflozin** (Jardiance)	10 - 25 mg 1x daily	
	Ertugliflozin (Steglatro)	5 - 15 mg 1x daily	
	Bexagliflozin (Brenzavvy)	20 mg 1x daily	

FDA Warning of DKA – Not approved for Type 1 (but used off-label)
 ~ increases risk of EDKA by 4-6%

Increased risk for those with type 2 on insulin + SGLT-2 Inhibitor
 Decreased insulin dose due to lower BG on SGLT-2 Inhibitors
 Can lead to insulin deprivation and ketoacidosis

157

Signs and Symptoms Euglycemic DKA

- ▶ Similar in presentation to hyperglycemic DKA.
- ▶ **Don't usually have polydipsia or polyuria since serum glucose is normal.**
- ▶ S/S include nausea, vomiting, shortness of breath, generalized malaise, lethargy, loss of appetite, fatigue, or abdominal pain.
- ▶ **Ill feeling individuals with diabetes plus malaise, dyspnea, nausea, or vomiting need to eval serum pH and get blood or urine ketone testing.**



Euglycemic Diabetic Ketoacidosis

Michael C. Plewa; Michael Bryant; Robin King-Thiele.

158

FDA NEWS RELEASE

FDA Authorizes First Wearable Device That Continuously Monitors Both Ketone Levels and Blood Sugar

New device can help people with diabetes detect warning signs of a dangerous complication before it becomes a medical emergency

For Immediate Release: August 25, 2026

The U.S. Food and Drug Administration today authorized the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for people aged 2 years and older living with diabetes. The Libre Duo 10 Day is the first wearable device in the U.S. that continuously monitors ketone levels, and the first in the world to continuously monitor both ketones and blood sugar (glucose) together in a single device.

"Today's authorization is a breakthrough for the safety of children and adults living with diabetes," said Michelle Tarver, M.D., Ph.D., Director of the FDA's Center for Devices and Radiological Health. "Knowing that ketone levels are rising, and having that information in real time, around the clock, can be the difference between early intervention and a life-threatening emergency."

159

	DKA	EDKA
Labs	DKA	EDKA
Glucose	200+	<200
Beta-hydroxybutyrate	3+	3+
Urine ketones	2+	2+
Blood pH	< 7.3	<7.3
Bicarb	<18	<18
Anion gap	>12	>12

ADA/EASD/AACE 2024 Hyperglycemic Crises in Adults Consensus Report

160

Poll Question 9

► RL is a 43 year old who was on insulin after experiencing GDM. She then was started on a GLP-1, Metformin and an SGLT-2, and stopped the insulin completely. Her daughter told her, "Your breath smells funny". A1C 7.9%. What are you worried about?

- a. Euglycemic DKA
- b. Dental caries
- c. Renal failure
- d. Steatosis



161

Poll Question 10


► Which of the following is true in the U.S.?

- A. Diabetes is the 3rd leading cause of death
- B. Cancer is more common in people with diabetes
- C. Cancer is the leading cause of death
- D. Diabetes starves tumors and decreases growth rate.

162

Cancer and Diabetes

- ▶ Diabetes is associated with increased risk of cancers of:
 - ▶ liver, pancreas, endometrium, colon and rectum, breast, and bladder.
- ▶ Association may result from shared risk factors between type 2 diabetes and cancer
 - ▶ Older age, obesity, and physical inactivity
 - ▶ May also be due to diabetes-related factors such as underlying disease physiology
 - ▶ Encourage people with diabetes to undergo recommended age- and sex-appropriate cancer screenings




4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2024

163

Leading Causes of Death in U.S.



Figure 4. Age-adjusted death rate for the 10 leading causes of death in 2024: United States, 2023 and 2024



- ▶ Cancer is the 2nd leading cause of death
- ▶ Diabetes is the 7th leading cause of death

Cancer and diabetes are diagnosed within the same individual more frequently than would be expected, even after adjusting for age.

<https://www.cdc.gov/nchs/products/databriefs/db548.htm>

164

What links Diabetes and Cancers?

- ▶ Hyperinsulinemia
- ▶ Hyperglycemia
- ▶ Inflammation



▶ CA Cancer J Clin. 2010 Jul-Aug;60(4):207-21. doi: 10.3322/caac.20078. Epub 2010 Jun 16.

Diabetes and cancer: a consensus report

Edward Giovannucci¹, David M Harlan, Michael C Archer, Richard M Bergenstal, Susan M Gapstur, Laurel A Habel, Michael Pollak, Judith G Regensteiner, Douglas Yee

Affiliations + expand

PMID: 20554718 DOI: 10.3322/caac.20078

165

Risk Factors Common to Diabetes & Cancer

- ▶ Aging
- ▶ Extra weight
- ▶ Diet
- ▶ Physical inactivity
- ▶ Ethnicity
- ▶ Alcohol
- ▶ Smoking
- ▶ Changes in the DNA?



Biologic links incompletely understood

166

Type 2 Diabetes and Cancer

- ▶ People with prediabetes and type 2
Two-fold higher risk for cancers of
 - ▶ Liver
 - ▶ Pancreas
 - ▶ Endometrium
- ▶ 1.2 to 1.5 fold risk of cancers of
 - ▶ Colon
 - ▶ Breast
 - ▶ Bladder.
- ▶ Lower risk of prostate cancer



Diabetes and Cancer: A Consensus Report Cancer J Clinic 2010
Joint statement American Cancer Society and American Diabetes Assoc

167

How Many People Die of Cancer Each Year?

Excluding non-melanoma skin cancer, **at least 40% of newly diagnosed cancers in US adults** — about 850,000 cases in 2026 — are potentially avoidable, including the 19% of cancers associated with cigarette smoking and 5% associated with alcohol consumption.

	Male			Female	
Lung & bronchus	63,040	19%	Lung & bronchus	61,950	21%
Prostate	36,320	11%	Breast	42,140	14%
Colon & rectum	30,110	9%	Pancreas	25,510	9%
Pancreas	27,230	8%	Colon & rectum	25,120	8%
Liver & intrahepatic bile duct	19,650	6%	Uterine corpus	14,450	5%
Leukemia	13,900	4%	Ovary	12,450	4%
Esophagus	12,940	4%	Liver & intrahepatic bile duct	11,330	4%
Urinary bladder	12,640	4%	Leukemia	10,010	3%
Non-Hodgkin lymphoma	11,710	4%	Brain & other nervous system	8,380	3%
Kidney & renal pelvis	10,200	3%	Non-Hodgkin lymphoma	8,250	3%
All sites	327,290		All sites	298,850	

Estimates are rounded to the nearest 10 and exclude basal cell and squamous cell skin cancers and in situ carcinoma except urinary bladder. Rank is based on modeled projections and may differ from observed data.

©2026, American Cancer Society, Inc., Surveillance, Prevention, and Health Services Research

<https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf>

168


ADA Standard 4 – Cancer Info

- ▶ Diabetes is associated with increased risk of liver, pancreas, endometrium, colon/rectum, breast, and bladder cancer.
- ▶ Shared risk factors between type 2 diabetes and cancer (older age, obesity, and physical inactivity) but may also be due to diabetes-related factors.
- ▶ Encourage regular cancer screenings & reduce modifiable cancer risk factors (obesity, physical inactivity, and smoking).
- ▶ **New onset of atypical diabetes (lean body habitus and negative family history) in a middle-aged or older person may precede the diagnosis of pancreatic adenocarcinoma.**

4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2026

169

Diabetes may be 1st sign of Pancreatic Cancer



170

Pancreatic Cancer



- ▶ Pancreatic cancer is only the 11th most common cancer in the US, it's the 3rd leading cause of death from cancer.
- ▶ No screening tests exists to catch it early.
- ▶ Watch for signs: Rapid developing hyperglycemia with wt loss. Usually in older individuals.
- ▶ 80% of time, people are not diagnosed with pancreatic cancer until after it's invaded nearby tissues or spread to other organs.
- ▶ Overall, only about 10% of people with pancreatic cancer will be alive 5 years after diagnosis.

<https://www.cancer.gov/news-events/cancer-currents-blog/2021/pancreatic-cancer-diabetes-early-detection> National Cancer Institute

171

MEDPAGE TODAY
Specialties - Perspectives - Health Policy - Meetings - Special Reports - Break Room - Resources - Society Partners


Oncology/Hematology > Other Cancers

'Grand Slam' Pancreatic Cancer Drug Wins FDA Approval

— RAS inhibitor dacomarib doubled survival outcomes in second-line trial

By Charles Gerstlitz, Senior Editor, MedPage Today

August 26, 2024 - 2 min read [Get MedPage Today on Google](#)



The FDA approved the first-in-class RAS inhibitor dacomarib (Rasquet) for metastatic pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer.

The [approval](#) stipulates use in adults with PDAC previously treated with at least one prior systemic regimen or that is ineligible for multiagent systemic therapy. The oral drug targets multiple isoforms of RAS, a driver mutation for most patients with PDAC.

"This drug showed unprecedented results in an area of high unmet need," said Angelo de Claro, MD, the director of FDA's Oncology Center of Excellence, in a statement. "The approval was granted 6.5 months before the user fee deadline, demonstrating the FDA's commitment to accelerating the approval of..."


172

Colorectal Cancer Screening Recommendations 2026

► All people at age 45 need screening for colon cancer




PHYSICIANS FROM THE AMERICAN COLLEGE OF GASTROENTEROLOGY want you to know that screening Colonoscopy can find growths in the colon called polyps so they can be removed before they turn into Colorectal Cancer.



<https://gi.org/topics/colorectal-cancer/>

173

Look at your Poop – Stool Chart

CLINICAL SIGNS & SYMPTOMS OF COLORECTAL CANCER


Change in Bowel Habits Persistent constipation, diarrhea, or narrowing of stool caliber (e.g., pencil-thin).	Gastrointestinal Bleeding Visible rectal bleeding (hematochezia) or dark, tarry stools (melena). Occult blood possible.	Unexplained Anemia Iron-deficiency anemia, often presenting with fatigue, weakness, and pale, especially in right-sided tumors.
Abdominal Discomfort Persistent abdominal pain, cramps, bloating, or a feeling of fullness.	Unintentional Weight Loss Significant, unexplained weight loss and loss of appetite (cachexia).	Tenesmus & Incomplete Evacuation A constant urge to have a bowel movement, feeling that the bowel does not empty completely (common in rectal cancer).

*Note: Early-stage CRC may be asymptomatic. Screening is crucial. [GI.org](https://gi.org) Graphic generated with AI tool Gemini 3.5 Flash

Everyone has different bowel habits. And stools can be different once in a while. If your stool is too hard or too loose or a change in color, let your healthcare provider know.

174

Diabetes Increases Hematologic Cancers and Mortality



<https://doi.org/10.1007/s00125-020-05338-7>

Association between diabetes and haematological malignancies: a population-based study
Diabetes Care 43(12):2020-2026

175

Poll question 11

- ▶ A 58-year-old without a history of diabetes is receiving treatment with an immune checkpoint inhibitor for metastatic melanoma. Four months after beginning therapy, presents with polyuria, weight loss, nausea, and fatigue. Laboratory findings include:

- Plasma glucose: 465 mg/dL
- Blood ketones: Positive
- Arterial pH: 7.18
- C-peptide: Undetectable

Which mechanism most likely explains this sudden hyperglycemia?

- ▶ A. Progressive insulin resistance caused chronically elevated cortisol levels
- ▶ B. Autoimmune destruction of pancreatic beta cells
- ▶ C. Glucocorticoid-induced hepatic glucose production
- ▶ D. Pancreatic exocrine insufficiency from chronic pancreatitis

176

Determine if Type 1 - Use AABCC Approach

- ▶ **Age**
 - ▶ e.g., for individuals <35 years old, consider type 1 diabetes
- ▶ **Autoimmunity**
 - ▶ e.g., personal or family history of autoimmune disease or polyglandular autoimmune syndromes
- ▶ **Body habitus**
 - ▶ e.g., BMI <25 kg/m²
- ▶ **Background**
 - ▶ e.g., family history of type 1 diabetes
- ▶ **Control**
 - ▶ e.g., level of glucose control on noninsulin therapies
- ▶ **Comorbidities**
 - ▶ e.g., treatment with immune checkpoint inhibitors for cancer can cause acute autoimmune type 1 diabetes or presence of other autoimmune conditions




1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes—2026

177

Checkpoint Inhibitors cause immune mediated diabetes

“treatment with immune checkpoint inhibitors for cancer can cause acute autoimmune type 1 diabetes”

Checkpoint Inhibitor–Associated Autoimmune Diabetes (CIADM) – A Systematic Review



2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026

Linda Wu, Venessa Tsang, Alexander M. Mencias, Sarah C. Sasson, Matteo S. Carlini, David A. Brown, Roderick Clifton-Bligh, Jenny E. Gunton; Risk Factors and Characteristics of Checkpoint Inhibitor–Associated Autoimmune Diabetes Mellitus (CIADM): A Systematic Review and Delineation From Type 1 Diabetes. Diabetes Care 1 June 2023; 46 (6): 1292–1299. <https://doi.org/10.2337/dc22-2202>


178

Immune Checkpoint Inhibitors (ICIs) in Oncology

Checkpoint Target	Mechanism of Action	Common Agents (Brand Names)	Primary FDA Indications
PD-1 (Programmed Cell Death Protein 1)	Blocks PD-1 receptors on T-cells, preventing tumor cells from shutting down T-cell activity.	• Pembrolizumab (Keytruda) • Nivolumab (Opdivo) • Cemiplimab (Libtayo)	Melanoma, Non-Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma, Hodgkin Lymphoma
PD-L1 (Programmed Death-Ligand 1)	Targets the ligand on tumor cells, preventing it from binding to and disabling T-cells.	• Atezolizumab (Tecentricq) • Durvalumab (Imfinzi) • Avelumab (Bavencio)	Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), Triple-Negative Breast Cancer
CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4)	Inhibits the CTLA-4 pathway during early T-cell activation in the lymph nodes, boosting overall immune response.	• Ipilimumab (Yervoy) • Tremelimumab (Imjudo)	Advanced Melanoma, Colorectal Cancer (MSI-H/dMMR), combined with PD-1 inhibitors for NSCLC/RCC

179

EMERGENCY ASSESSMENT & TRIAGE: IMMUNE CHECKPOINT INHIBITOR (ICI)-INDUCED DIABETES



The most likely immune checkpoint inhibitors that trigger rapid, autoimmune-mediated destruction of beta cells include:

- anti-PD-1 (i.e., nivolumab and pembrolizumab) and
- those that target programmed cell death protein ligand 1 (PD-L1) (i.e., durvalumab and avelumab).
- Hyperglycemia as a result of ICIs can occur at any time after the initiation of therapy —as quickly as 1 week after the first dose to up to 12 months after.

180

PI3K Inhibitors

- ▶ PI3K inhibitors used primarily to treat:
 - ▶ advanced breast cancer (specifically HR+/HER2- tumors with PIK3CA mutations) and
 - ▶ blood cancers (such as lymphomas, leukemias, and follicular lymphoma).
- ▶ Phosphatidylinositol 3-kinase (PI3K) inhibitors are small molecules designed to disrupt intracellular signaling pathways, thereby inhibiting cancer cell growth and survival.
- ▶ Within this class, targeted inhibition of the alpha isoform (PI3K α) disrupts downstream insulin receptor signaling, frequently resulting in profound, on-target hyperglycemia and acute insulin resistance.




ADA Standard 9 2026 <https://doi.org/10.2337/dc26-S009>

181

PI3K α Inhibition

MECHANISM OF ON-TARGET HYPERGLYCEMIA INDUCED BY PI3K α INHIBITION.



Graphic generated with AI tool Gemini 3.5 Flash

182

Which PI3K α medications are associated with glucose elevations?

Alpelisib and inavolisib

- ▶ These two PI3K α inhibitors have a 60% incidence of causing hyperglycemia, typically appearing within the first 2 weeks of therapy.
- ▶ People at increased risk of hyperglycemia from PI3K α inhibitor therapy include those with:
 - ▶ preexisting prediabetes
 - ▶ BMI >25
 - ▶ age >65 years
 - ▶ being treated with glucocorticoid.
- ▶ Glucose management is crucial since significant hyperglycemia can lead to discontinuation and/or reduction in PI3K α medication dose, which can decrease therapy efficacy.

ADA Standard 9 2026 <https://doi.org/10.2337/dc26-S009>

183

Treatment for Hyperglycemia secondary to PI3Kα Inhibitors

- ▶ **Metformin is the first-line oral agent to treat PI3Kα inhibitor-induced hyperglycemia.**
 - ▶ Proactive use of metformin may prevent hyperglycemia
 - ▶ Consider potential adverse effects of metformin therapy, particularly diarrhea, which is also a frequent adverse effect of PI3Kα therapy.
- ▶ **Pioglitazone** is also an option as monotherapy or in combination with metformin, but its slow onset of action can limit its effectiveness.
- ▶ **SGLT2 inhibitors** have also shown efficacy, but close monitoring is needed, as ketoacidosis has been reported.
- ▶ **Meds to Avoid**
 - ▶ **Only consider Insulin and sulfonylureas as a last resort.**
 - ▶ Increased insulin levels may reactivate the PI3K pathway, counteracting the antitumor effects of PI3K inhibition.
 - ▶ **Avoid using GLP-1 RAs with PI3K inhibitors-**
 - ▶ Treatment is not recommended at this time due to their uncertain effect on PI3K inhibitor efficacy (based on their increase in insulin secretion) and the potential to cause nausea and vomiting.

ADA Standard 9 2026 <https://doi.org/10.2337/dc26-S009>

184

What Can Health Professionals Do?

- ▶ Be aware of treatments and medications that can cause sudden hyperglycemia.
- ▶ Promote healthy foods, activity, quit smoking, and resources.
- ▶ **Encourage appropriate screening for cancer and to report any symptoms**
- ▶ Focus on **prevention** of diabetes



185

Modifiable Risk Factors

- ▶ **Quit Smoking:** Cigarettes smoking is leading preventable cause of cancer, linked to 20% of all cancers and 30% of cancer deaths. Both direct and secondhand smoke cause significant DNA damage.
- ▶ **Ultraviolet (UV) Radiation:** Exposure to excessive sunlight and indoor tanning beds damages skin cells, significantly increasing the risk of melanoma and other skin cancers.
- ▶ **Infectious Agents:** Some cancers are driven by preventable viral and bacterial infections, primarily Human Papillomavirus (HPV) and Hepatitis B and C. Promote screening and vaccinations.
- ▶ **Get enough sleep**



Meet with RDN!

- Less meat, processed foods.
- More fiber, whole foods
- Consider decreasing alcohol consumption

Get active - reduces risk of colon, post-menopausal breast and endometrial cancer.

186

DIABETES CLASSIFICATION ALGORITHM
DIABETES DIAGNOSIS: A1C $\geq 6.5\%$ (48 mmol/mol) | FPG ≥ 126 mg/dL (7 mmol/L)
 2h 75g OGTT ≥ 200 mg/dL (11.1 mmol/L) | Random Glucose ≥ 200 mg/dL (11.1 mmol/L) + Symptoms



- ▶ But, doesn't want to inject insulin every day.
- ▶ Now what?




 Diabetes Education RESOURCES 25 YEARS Download Success! Get Our Free iOS/Android Apps  						
Action		Insulin Name	Onset	Peak	Duration	Considerations
Bolos	Very Rapid Acting Analogs	Aspart (Fiasp)	16 - 20 min	1 - 3 hrs	5 - 7 hrs	Bolus insulin lowers after-meal glucose. Post meal BG reflects efficacy
		Lispro-aabc (Lyumjev)	15 - 17 min	2 - 3 hrs	5 - 7 hrs	
	Rapid Acting Analogs	Aspart (Novolog / Merilog/ Kirsty)	20 - 30 min	1 - 3 hrs	3 - 7 hrs	Basal insulin controls BG between meals and nighttime. Fasting BG reflects efficacy
		Lispro (Humalog™ / Admelog)	30 min	2 - 3 hrs	5 - 7 hrs	
	Short Acting	Glulisine (Apidra)	15 - 30 min	1 - 3 hrs	3 - 4 hrs	
	Intermediate	Regular*	30 - 60 min	2 - 4 hrs	5 - 8 hrs	
Basal	Long Acting	NPH	2 - 4 hrs	4 - 10 hrs	10 - 16 hrs	Side effects: hypoglycemia, weight gain
		Glargine (Lantus® / Basaglar® / Semglee® / Revloglar® / Tresiba®)	2 - 4 hrs	No Peak	20 - 24 hrs	Typical dosing range: 0.5-1.0 units/kg body wt/ day
	Ultra Long	Gludec® (Lantus®) / Icodec® (Awiqal) Once Weekly U-700	~ 1 hr	< 42 hrs		
Basal + Bolus	Intermediate + short	Combo of NPH + Reg 70/30 = 70% NPH + 30% Reg 50/50 = 50% NPH + 50% Reg	16 - 18 hrs	2 - 4 days	> 7 days	Discard most open vials after 28 days. For pen storage guidelines, see package insert.
	Intermediate + rapid	Novolog® Mix - 70/30 Humalog® Mix - 75/25 or 50/50	30 - 60 min	Dual peaks	10 - 16 hrs	
			5 - 15 min		24 hrs	

What Is Insulin Icodec?

► **What Is Insulin Icodec?**

► Insulin icodec (brand name *Awiqli*®) is the **first once-weekly basal insulin analog** designed to provide steady glucose control over **7 days** with a **single injection**.


How it Works: Albumin Binding Depot



► Unlike traditional basal insulins, icodec is engineered to:

- Bind to albumin in the bloodstream, creating a circulating depot
- Release insulin slowly over the course of a week
- Maintain stable basal insulin levels with fewer peaks and troughs

Injection Count: A Meaningful Shift



This innovation **reduces** injections **from 365 to just 52**, a meaningful shift for many people living with diabetes.

190

Pharmacology Spotlight: Why Insulin Icodec Is Unique

► **Once-weekly, ultra-long-acting basal insulin formulated at U-700 concentration (700 units/mL).**

► **Half-life of about one week**, reaches steady state after several weekly doses, with minimal peak-to-trough variability.

► Because of this prolonged action, dose adjustments must be made thoughtfully, as changes take longer to fully manifest.



191

Clinical Efficacy: What Does the Evidence Show?

► The **ONWARDS Phase 3 clinical program** (≈4,000 participants with type 2 diabetes) demonstrated:

- A1C reduction comparable to once-daily basal insulin
- Non-inferiority to standard basal insulins like degludec or glargine
- Similar risk of hypoglycemia
- Slightly increased time in range

► For clinicians, this means:

- 👉 Similar outcomes
- 👉 With fewer injections
- 👉 And potentially happier people



192

Dosing & Titration Insulin Icodec

- ▶ Dosing is typically based on the person's **current total daily basal insulin dose**, with the goal of maintaining equivalent weekly insulin exposure.
- ▶ Multiply the existing **daily basal dose by 7** to estimate the initial once-weekly dose, followed by careful titration based on fasting glucose trends.
- ▶ If **insulin-naïve**, a standard starting dose (e.g., 70 units once weekly in clinical trials) may be used, with adjustments made weekly or every few weeks depending on glycemic response.
- ▶ **Individualization is key**—consider factors such as hypoglycemia risk, renal function, and patient ability to monitor glucose when determining and adjusting the dose.
- ▶ **Dose Adjustment in Altered Kidney Function** –
 - ▶ eGFR of 50 or greater – no dosage adjustment needed.
 - ▶ eGFR of 10-50 – administer 75% of the usual starting dose.
 - ▶ eGFR less than 10 – administer 50% of usual dose.

193

Packaging and Storage

- ▶ **Icodec insulin is available in 3 different pen sizes and has a 12 week shelf life at room temperature.**
- ▶ Pens can be dialed in 10-unit increments with a maximum dose of 700 units.

Download our [Insulin Storage and Dispensing Info](#)




Insulin Storage and Dispensing Info

Product Name/Type	Expiration when opened, stored at room temp up to 86 F	Pens per Box Or Vial	Units per Pen/Vial	Max Dose / Notes
Basal Insulins - Long and Ultra Long Acting				
Glargine (Lantus) Biosimilars: Basaglar Semglee/Rezvoglar - Pen Delivery - Vials; Lantus, Semglee	28 Days 28 Days	5 Pens 1 Vial	300 units in 3 mL 1000 Units	80 Units
Degludec (Tresiba) - Pen	56 Days	5 Pens	300 units in 3mL	80 Units
Icodec (Awiq) U-700 Once weekly injection	12 weeks	1 pen/pack with needles	700 units in 1.0 mL 1050 units 1.5 mL 2100 units in 3mL	Max dose 700 units. Flex Touch Pen dials in 10-unit dosing increments.

194

Population Health Management

- ▶ Diabetes registries
- ▶ Screening programs
- ▶ Health equity initiatives
- ▶ Community outreach



195

The ABC's of Diabetes Management

- A** - A1c less than 7%, TIR 70%
- B** - Blood pressure < 130/80
- C** - Cholesterol
LDL < 70, HDL > 40, Triglycerides < 150
- D** - Drugs- Keep list on phone
- E** - Exercise and Eyes
- F** - Food and Feet
- G** - Glucose checks and goals
- H** - Healthy Coping - Hoorah for your hard work!
- K** - Kidneys - Check UACR & GFR



196

Mahalo



- Questions?
- Email: info@diabetesed.net
- Web: www.diabetesed.net
- Phone 530-893-8635



197
